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Abstract
Background: The objective of reported study was to evaluate the clinical utility of prenatal microarray testing for
submicroscopic genomic imbalances in routine prenatal settings and to stratify the findings according to the type
of fetal ultrasound anomaly.
Methods: From July 2012 to October 2015 chromosomal microarray testing was performed in 218 fetuses with
varying indications for invasive prenatal diagnosis: abnormal karyotype, ultrasound anomalies, pathogenic variant in
previous pregnancy or carriership in a parent.
Results: The detection rate in the group of fetuses with ultrasound anomalies was 10,0% for pathogenic copy
number variants (CNVs), five of them being larger than 8 Mb and expected to be seen on prenatal karyotype. If
only those pathogenic CNVs below the classical karyotype resolution are considered, chromosomal microarray
testing provided an additional 7,7% diagnostic yield in here reported series. When stratified according to the
ultrasound anomalies, the highest percentage of pathogenic CNVs were detected in the group of fetuses with
multiple congenital anomalies (16,7%) and lowest in the group of isolated in utero growth restriction (6,3%). In the
group of cases with isolated increased nuchal translucency we identified a small interstitial deletion of 16p24.1
involving FOXF1 gene. Prenatal aCGH also provided important insights into cases with seemingly balanced
chromosomal rearrangements found on prenatal karyotype, where additional pathogenic CNV were discovered.
Conclusion: Prenatal chromosomal microarray testing significantly increases the diagnostic yield when compared
with conventional karyotyping. The highest added value is shown in prenatal diagnostics in fetuses with abnormal
ultrasound results. Variants of unknown significance and risk factor CNVs present important challenges and should
be discussed with parents in advance, therefore pretest counseling prior to prenatal testing is very important.
Background
Genetic testing in the prenatal period has significant
implications for fetuses with ultrasound anomalies.
When a structural anomaly is discovered in an unborn
fetus, it is important to evaluate if it has a genetic origin
and whether potentially other clinically important fea-
tures might be expected, or if it is an isolated finding
with good clinical prognosis after surgical intervention.
Ongoing technological developments and knowledge
advancements in the last two decades have expanded the
spectrum of possible prenatally detected genomic aber-
rations. With this progress we are able to detect and
clinically interpret smaller and smaller genomic imbal-
ances and comparative genomic hybridisation using
microarray technology (arrayCGH, aCGH, chromosomal
microarrays, molecular karyotyping) has succesfully
replaced classical karyotyping in postnatal and prenatal
setting. It is a first tier test in patients with developmental
delay, intellectual disability, autism spectrum disorders
and/or multiple congenital anomalies, with significant in-
crement in the diagnostic utility [1, 2]. In recent years it is
becoming widely applied in the prenatal setting, where it
is recommended for routine prenatal diagnostic testing in
the fetuses with ultrasound anomalies [3, 4]. A large pro-
spective and retrospective studies have shown a 5–10% in-
crease in the detection of clinically relevant copy number
variation in the fetuses with ultrasound anomalies, as
compared to conventional karyotyping [5–7]. Further-
more, recently 17 studies were evaluated by Grande et al.
[8] to investigate the impact of aCGH testing in the group
of fetuses with isolated increased nuchal translucency
* Correspondence: lucalovrecic@gmail.com
Clinical Institute of Medical Genetics, University Medical Centre Ljubljana,
Slajmerjeva 3, SI-1000 Ljubljana, Slovenia
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Lovrecic et al. BMC Medical Genetics  (2016) 17:81 
DOI 10.1186/s12881-016-0345-8
NT > 3,5 mm. Their review suggested 5% incremental
yield of the aCGH analysis over classical karyotyping. A
small number of studies have assessed the clinical utility
of chromosomal microarrays in all pregnancies which
underwent the invasive prenatal procedures and reported
a copy number abnormality in 1.7% of fetuses with a
normal ultrasound scan where the indication for invasive
testing was an advanced maternal age or a positive aneu-
ploidy screening test [7]. Based on that, the authors
suggest that the aCGH might be used in all prenatal
testing, regardless of indication. Indeed, some countries
have implemented just such a consensus approach
and established an Ad Hoc Committee to assist with
ambiguous results [9].
It is widely accepted that chromosomal microarrays
are the first tier test in prenatal settings in fetuses with
ultrasound anomalies or/and increased NT > 3,5 mm. At
the same time, the inevitable challenge present the
potential to detect variants of unknown significance
(VOUS), therefore performing the test in all prenatal
cases is currently not a general recommendation. The
VOUS frequency in all prenatal samples is estimated to
be 0.3–1%, depending on resolution and type of the plat-
form used [10, 11].
In Slovenia, the prenatal aCGH is currently performed
in the high-risk pregnancy cohort, where the fetal ultra-
sound examination is abnormal, increased NT >3,5 mm is
seen, or de novo balanced translocation detected or where
one parent is a carrier of a pathogenic CNV. We report
on our diagnostic, counseling and pregnancy outcome ex-
perience in the period from July 2012 to October 2015 in
218 prenatal cases.
Methods
The samples and the DNA isolation
The prenatal samples of amniotic fluid, chorionic villi,
fetal blood and fetal tissue were received in the period
from July 2012 through October 2015 mainly from the
in-house ultrasound unit of The Division of Gynaecol-
ogy and Obstetrics and through our Genetic Counseling
outpatient clinic, in total 218 cases. Patients/pregnant
couples received the pre-test genetic counseling, includ-
ing discussion about potential finding of VOUS. An in-
formed consent was obtained. All pathogenic CNVs and
VOUS were discussed with patients during post-test
genetic counseling. In 18 cases there was a known
abnormal fetal karyotype (balanced/unbalanced trans-
location/rearrangement or marker chromosome) or fam-
ily history of a chromosome rearrangement in a parent
or previous pregnancy. The remaining 200 samples were
received in line with the other indications and were
further categorized into different groups, based on the
type and combination of ultrasound anomaly. The DNA
was extracted from direct or cultured chorionic villi,
direct amniotic fluid, cultured amniocytes, fetal blood or
fetal tissue according to the manufacturer’s protocol using
Qiagen Mini kit (Qiagen, Valencia, CA). Quality and
concentration parameters of the DNA were measured
with NanoDrop 2000c spectrophotometer (Thermo
Fisher Scientific Inc.) and Qubit 2.0 fluorometer (Life
Technologies Inc.).
Microarrays
Following sample extraction, DNA was processed accord-
ing to Agilent protocol (Version 7.3 March 2014) using
commercially available male and female genomic DNA
(Agilent Technologies, Human Reference DNA, Male and
Female) or in-house DNA reference mix as a reference
DNA. Agilent SurePrint G3 Unrestricted CGH ISCA v2,
8x60K microarrays were used which provide a practical
average resolution of 100 kb. Array images were acquired
using Agilent laser scanner G2565CA, image files were
quantified using Agilent Feature extraction software for
Cytogenomics 3.0 and analysed with Agilent Cytoge-
nomics 3.0 software (Agilent Technologies).
Classification of results
Called CNVs were aligned with known aberrations in
publically available databases - ClinGen (http://dbsearch.
clinicalgenome.org/search/), DECIPHER (Database of
Chromosomal Imbalance and Phenotype in Humans using
Ensembl Resources https://decipher.sanger.ac.uk/), ClinVar
(http://www.ncbi.nlm.nih.gov/clinvar/), Database of Gen-
omic Variants - DGV (http://dgv.tcag.ca/dgv/app/home), as
well as with the in-house database of detected variants and
their clinical significance, ascertained by the trained ana-
lysts. All called CNVs were classified in the three groups,
benign, VOUS and pathogenic, according to ACMG Stan-
dards and Guidelines [12]. In addition, some of the discov-
ered and reported CNVs were not related to the phenotype
and were therefore classified as secondary findings. We
prefer this terminology over "incidental finding", because in
the genome-wide aCGH, such findings may be anticipated
and cannot be termed "incidental". The possibility of a
secondary finding was discussed with the pregnant couple
in the pretest counseling session and identified variants
were reported back to the family. The CNVs were classified
as benign if they were reported in the above mentioned
databases as benign, or present in our in-house database in
more than 1% of the cases. The pathogenic CNVs were
either known microdeletion/microduplication syndromes
or large genome copy number gains and losses, described
as pathogenic in the scientific literature. Variants classified
as VOUS were either already present in cited databases as
VOUS or bigger than 200 kb with OMIM gene content.
Both the pathogenic and VOUS CNVs were communicated
to the parents. The parental blood samples were collected if
VOUS or secondary finding was detected in the fetus.
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Results
The group of fetuses with abnormal fetal karyotype or
known carrier status of one of the parents
Four prenatal samples (4/218, 1,8%) were tested because
of known carrier status in the pregnant women and 14
(14/218, 6,4%) samples were cases with known abnormal
fetal karyotype.
In the first group there were three mothers with a
carrier status, one of them had had two pregnancies in
the reported period. She is a carrier of a large Xq21q23
duplication and has a mild intellectual disability with no
other health related issues or dysmorphic features. The
duplication was confirmed in her male fetus, but not in
her female fetus in the subsequent pregnancy. The sec-
ond female has partial IL1RAPL1 gene (OMIM*300206)
deletion and a son and a brother with the same deletion.
Both males had mild intellectual disability and behavioural
problems. The same deletion was confirmed in her male
fetus. The third female is a TAR (thrombocytopenia absent
radius syndrome; OMIM#274000) deletion carrier and her
previous pregnancy was terminated due to the confirmed
TAR syndrome in the fetus. In her following pregnancy,
the fetal sample anaysis identified inherited deletion, but
not the hypomorphic nucleotide change on the second
allele, present also in the father.
The second group consists of 14 cases in which con-
ventional karyotype analysis showed de novo balanced
translocation or unbalanced rearrangement inherited
from balanced parent translocation (9 cases), or marker
chromosome (5 cases). Details are shown in Table 1.
Performed aCGH in a fetus with complex, seemingly
balanced translocation involving chromosomes 7, 8 and
12 (Case 1) again proved there were no CNVs at the
breakpoints (7q,8q,12q), but identified deletion spanning
3,7 Mb in the short arm of the chromosome 12 (12p12.1).
Similarly, chromosomes 1 and 5 were involved in the de
novo translocation in case 5, but the aCGH revealed
2,5 Mb large deletion at 2q24.3.
Five cases with marker chromosomes were detected
using classical karyotyping, four of them were further
characterised by FISH. In the remainig case (Case 10,
Table 1), a marker was lost on chorionic villi culture.
Amniocentesis was performed and no marker chromo-
some detected. The pregnancy was continued and healthy
female was born.
Additional aCGH testing in the cases 11, 12 and 14
(Table 1) did not confirm any unbalanced genomic re-
arrangement. Further UPD testing was performed for
chromosome 14 or 15, depending on the FISH analysis
(UPD15 in the case 11 with marker chromosome derived
from chromosome 15; UPD14 in the cases 12 and 14
with positive FISH results for centromere 14 or 22).
UPD was excluded in all three cases.
The group of fetuses with ultrasound anomalies
In all of the following reported cases (n = 200, 91,7%)
rapid aneuploidy QF-PCR test for detection of numerical
aberrations of chromosomes 13,18, 21, X and Y was
performed and reported as normal. Overall, the aCGH
detection rate for causative pathogenic CNVs was 7,0%
(14/200) and for VOUS 2,5% (5/200). Details are shown in
Table 2. In addition, secondary findings were identified in
Table 1 Results of conventional karyotyping and aCGH in prenatal cases with translocations or marker chromosomes
Case Karyotype aCGH result
1 46,XY,t(7;8;12)(q34;q21.1;q12)dn,inv(9)(p12q13)pat 12p12.1(21,356,582-25,062,714)x1
2 46,xy,t(4;10)(p16.3;q21.2)dn Normal profile
3 46,XX,t(3;16)(p?14;p13)dn Normal profile






9 46,XX,t(3;11)(q21;q14.2) Normal profile
10 47,XX,+mar[6]/46,XX[50]a Normal profile
11 47 XY,+mar dn.ish idic(15)(D15Z4++) Normal profile




Yq11.21q12(14,576,544–59,002,403) × 2 ~ 3,
Yq12qter(59,028,692–59,335,913) × 1 ~ 2
14 47,XX,+mar mat.ish der (14/22)(D14Z1/D22Z1)x2,(Acro-P-Arms)x2 Normal profile
aresults from chorionic villi sample; amniocentesis was performed later and no marker chromosome detected. Healthy female was born
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Table 2 The details of clinically significant copy number variations in the fetuses with ultrasound anomalies
Case number Ultrasound findings aCGH results CNV size CNV classificationa Related syndrome/gene or literature
and comments
1 Structural heart anomaly, Hydrops arr[hg19] 1p36.33p36.31(779,727–6,377,318)x1 dn 5,8 Mb P 1p36 deletion syndrome (OMIM#607872)
2 Bilateral radial aplasia arr[hg19] 1q21.1q21.2(145,415,190–145,799,602)x1 mat 385 kb P* TAR syndrome (OMIM#274000)
3 Bilateral radial aplasia arr[hg19] 1q21.1q21.2(145,415,190–145,799,602)x1 385 kb P* TAR syndrome (OMIM#274000)






1q21.1 deletion syndrome (OMIM#612474),
including GJA5 gene
5 Spina bifida, hydrocephalus, polydactyly arr[hg19] 2p25.3p22.1(23,938–41,524,241)x3 41,5 Mb P Derived from maternal balanced translocation
6 Cystic hygroma arr[hg19] 2p16.3(51,109,690–51,251,557) × 1 141,8 kb SF, P** NRXN1 gene (OMIM*600565)
7 IUGR arr[hg19] 2q13(111,442,130–113,065,779) × 1 pat 1,6 Mb VOUS 2q13 deletion syndrome [21, 22]
8 Ventriculomegaly, ACC arr 2q33.3q35(208,814,372–219,814,526)x3 dn 11 Mb P De novo, many genes
9 Upper limb anomalies arr[hg19] 5p13.2(36,952,801–37,024,752)x1 dn 72 kb P CdL syndrome (OMIM#122470)
10 Multiple congenital anomalies arr[hg19] 6p25.3p25.1(206,749–5,507,458) × 3 dn 5,3 Mb P ORPHA1745
11 Ambiguous genitalia (karyotype 46,XY) arr[hg19] 9p24.3(220,253–1,999,170)x1 mat 1,7 Mb P 9p24.3 deletion syndrome, 46,XY sex reversal
(OMIM#154230)
12 Multicystic kidney arr[hg19] 15q11.2(22,765,628–23,217,514) × 1 mat 452 kb VOUS 15q11.2 risk factor locus, inherited from the
mother with mild learning diffuculties
13 Cystic higroma, IUGR arr[hg19] 15q13.2q13.3(30,653,877–32,861,626) × 3 dn 2,2 Mb LP 8 OMIM genes, DECIPHER cases
14 Pyelectasis, short femur arr[hg19] 16p13.3(1,917,269–2,527,114) × 3 pat 610 kb VOUS Inherited from healthy father
15 Multiple congenital anomalies arr[hg19] 16p13.12p11.2(14,145,698–29,331,350) × 3 dn 15,2 Mb P De novo, many genes
16 IUGR, multicystic kidney arr[hg19] 16p12.2(21,837,492–22,407,931) × 1 mat 570 kb SF, P** 16p12.1 deletion syndrome (OMIM#136570)
17 Multiple congenital anomalies arr[hg19] 16p11.2(29,592,783–30,190,568) × 3 dn 610 kb SF, P** 16p11.2 duplication syndrome
(OMIM#614671)
18 Bilateral pes equinovarus arr[hg19] 16p11.2(29,673,954–30,190,568) × 1 pat 516 kb SF, P** 16p11.2 deletion syndrome (OMIM#611913)
19 Vertebral anomalies, scoliosis arr[hg19] 16p11.2(29,673,954–30,190,568) × 1 516 kb SF, P** 16p11.2 deletion syndrome (OMIM#611913)
20 Increased NT arr[hg19] 16q24.1(86,211,031–86,649,743) × 1 dn 439 kb P FOXF1 (OMIM*601089)
21 Occipital meningocele arr[hg19] 18p11.32p11.21(148,963–14,081,887) × 4 dn 13,9 Mb P 18p tetrasomy (OMIM#614290)




P Derived from paternal inversion of
chromosme 20
23 Bilateral cleft lip and palate arr[hg19] 22q11.21(20,659,547–21,440,514)x3 pat 781 kb SF, P** Atypical 22q11.2 duplication syndrome (OMIM#608363)
24 Hypoplastic nasal bone, cystic formation
in abdomen
arr[hg19] Xp22.31(6,488,721–8,097,511) × 2
mat (male fetus)
1,6 Mb VOUS Xp22.31 duplication [23]
25 Complex structural heart anomaly arr[hg19] Xq13.3(74,463,757–74,651,249) × 3
(female fetus)
188 kb VOUS ZDHHC15(OMIM*300576)
aP-pathogenic, VOUS –variant of unknown significance, B - benign, SF - secondary finding; P*hypomorphic nucleotide change on the second allele; P**-microdeletion/microduplication with reduced penetrance;













7 cases (7/200, 3,5%). These CNVs were part of known
microdeletion/microduplication syndromes or single gene
deletions with incomplete penetrance and were discussed
case by case, by the professional committee within our
department before being reported back to the families.
Among 14 clinically significant CNVs, five were larger
than 8 Mb and therefore expected to be seen if classical
prenatal karyotyping had been perfomed. The remaining
9 clinically relevant pathogenic CNVs below the classical
karyotype resolution represent an additional 4,6% diag-
nostic yield in this reported series. In some cases, follow
up studies using FISH and classical karyotype analysis
were needed in order to elucidate the mechanism and
origin of the identified CNV and to be able to estimate
the recurrence risk. For example, in the case 22 (Table 2)
conventional karyotyping was performed post aCGH as
recombinant chromosme 20 was suspected. This was
confirmed and parental studies showed a paternal origin
(paternal chromosome 20 inversion). The unbalanced
rearrangement in case 5 (Table 2) was also shown to be
inherited from the maternal balanced translocation.
In all 5 cases of VOUS these were reported back to
the parents, as the parents' blood samples are not col-
lected routinely at the time of the prenatal sampling
(amniotic fluid, chorionic villi), but are taken later if re-
quired. All couples are informed accordingly during the
pretest counseling session.
The two hundred cases of fetuses with ultrasound
anomalies were further categorized into the four following
subgroups: isolated increased nuchal translucency (NT >
3.5 mm; 35 cases), intrauterine growth restriction (IUGR;
16 cases), single organ system anomaly (89 cases), multiple
congenital anomalies (structural anomaly in two or more
organ systems; 60 cases). As expected, the highest
percentage of pathogenic CNVs was confirmed in the
group of fetuses with multiple congenital anomalies
(10,0%; 6/60) and the lowest in the group of fetuses with
isolated IUGR (0/16), but these numbers are too low to be
statistically significant. Further details are presented in the
Fig. 1 and Table 2.
The heterogeneous group of 89 fetal cases with single
organ system anomaly was subcategorized into 7 groups,
in order to define common anomalies, as shown in the
Fig. 2. Most of the fetuses (63%) had an isolated anomaly
of the central nervous system or the heart or the musculo-
skeletal system. The diagnostic yield of the clinically rele-
vant pathogenic CNVs in the joint group of 89 fetuses was
5,6% (5/89), with the additional 2 cases where VOUS was
identified. Only one CNV was big enough to be likely
visible using the conventional karyotype analysis.
Discussion
Diagnostic aCGH has a well established role in the pre-
natal genetic diagnostics in fetuses with increased nuchal
translucency or other ultrasound anomalies. The higher
diagnostic yield and the reduced turnaround time attrib-
utable to this method, outweigh its potential to discover
VOUS, which can be minimised by the concurrent par-
ental analysis. Obtaining specific genetic diagnosis adds
essential information about the potential full phenotypic
expression beyond detected ultrasound anomalies and
the postnatal prognosis. Furthemore, it has important
information for future pregnancies and risk of recur-
rence in the families.
Additional diagnostic yield of array CGH in this re-
ported series was 4,6%. There were three published studies
of the diagnostic utility of microarrays in fetuses with
ultrasound anomalies with a higher number of cases
(Table 3) and they report diagnostic yield of 6,3% [5], and
6% [6, 7]. A slightly lower number in our report might be
due to the inclusion criteria and categorization of cases.
For example, in the study reported by Shaffer et al.[5] all
pathogenic CNVs were considered in the reported
percentages, including those bigger that 10 Mb. The diag-
nostic yield in our group of fetuses with multiple congeni-
tal anomalies was even higher (10,0%), which was
expected, and reported by authors in the previous studies
(9,5% [5], and 15,4% [13]).
The highest proportion of pathogenic CNVs was identi-
fied among the cases with musculoskeletal abnormalities.
Allthough the numbers in our group were too small to
make any further conclusions, the same finding was
reported in the biggest study so far [5]. Among these cases
we encountered two fetuses with thrombocytopenia-
absent radius syndrome - TAR (OMIM#274000) and in
both cases we confirmed compound heterozygosity for
typical 1q21.1 deletion and the hypomorphic nucleotide
change in the RBM8A gene on the other allele. Further-
more, we discovered an intragenic NIPBL deletion
(Cornelia de Lange syndrome, OMIM#122470) in a fetus
with reduction anomaly of the upper limbs and dys-
morphic features. In the group of fetuses with the isolated
increased nuchal translucency a small interstitial 16q24.1
deletion was identified, involving FOXF1 gene (Alveolar
capillary dysplasia with misalignment of pulmonary veins,
ACDMPV, OMIM#265380) and FOXC2 gene (Lymph-
edema-distichiasis syndrome, OMIM#153400). This is the
first report linking the deleted FOXF1 region to abnormal
ultrasound findings in the first trimester. The post-
mortem histopathology examination confirmed ACDMPV
in the fetus. There has been one prenatal case reported in
the literature with septated cystic hygroma, fetal hydrops,
and a single umbilical artery presented at the 18th weeks
of gestation, in which aCGH identified a deletion of
1,1 Mb in size, including both FOXF1 and FOXC2 [14]. In
addition, postnatal ACDMPV with or without additional
congenital anomalies has been shown to be linked to this
region in 2009 [15]. Until recently the prenatal aCGH was
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predominantly used in the fetuses with structural ultra-
sound anomalies and only a minority of the studies
reported results in the group of fetuses with the isolated
increased NT. We expect to see other reports of the
FOXF1 deletions linked to increased NT.
Besides array CGH being the first tier test in the pre-
natal cases with abnormal ultrasound findings, it also
proves to be crucial as a complementary method to
classical karyotyping in specific prenatal scenarios. In
our small cohort of 4 prenatal cases of seemingly
balanced chromosomal rearrangements the unbalanced
rearrangement was found in two cases. Furthermore,
the identified rearrangements were both outside the
putative breakpoints locations. Cryptic chromosomal
rearrangements have been previously discovered not
only at the translocation breakpoints, but elsewhere in
the genome in the cases of apparently balanced karyo-
type, as well [16, 17]. This is highly relevant informa-
tion in the group of fetuses with normal ultrasound
results, where apparently balanced translocation is dis-
covered after prenatal testing for other indications (ma-
ternal age or positive 1st trimester screening results).
Fig. 1 The diagnostic yield of the aCGH in four groups of the prenatal samples, divided according to the categories of ultrasound anomalies. The
absolute numbers of cases in each of the four groups are shown on X-axis, according to the aCGH results - normal results (grey), VOUS/secondary
findings (black) and causative pathogenic CNVs (marble). Y-axis represents the four groups of prenatal samples according to the ultrasound
anomalies/measurements. NT - nuchal translucency, IUGR - intrauterine growth restriction
Fig. 2 The representation of single system anomalies in the group of the prenatal samples
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Although the aCGH is superior to the classical karyo-
type in most cases, the latter has proven to be essential
to elucidate the mechanism, origin and recurrence risk
in certain cases, as illustrated by the cases 5 and 22
(detailed in Table 2). These cases illustrate the import-
ance of the fetal backup culture in order to have it avail-
able for the follow up studies, and highlights the need
for integration of aCGH and cytogenetics.
Performing aCGH in prenatal settings introduces
important challenges when genome wide approach is
used, because of the potential to identify the CNV cate-
gorized as risk loci or VOUS. It is generally recom-
mended, that VOUS and some of the low penetrance
risk loci are not reported back to future parents. Some
laboratories have their own national or institutional rules
with respect to the reporting of these findings [9]. It is
important to stress that when deciding not to report
specific CNV, there should be different protocols imple-
mented for the laboratory procedures, interpretation and
reporting. Moreover, one should specify if such findings
should be archived in the laboratory or directly to med-
ical files. And if so, when to be communicated with the
parents/patients. Due to these challenges and due to the
fact, that parental samples are not collected concur-
rently, we reported back discovered VOUS. In our group
of fetuses with ultrasound anomalies, altogether five
CNVs classified as VOUS were discovered. After testing
the parents it added additional information to these situ-
ations and indeed, in four out of five cases these were
inherited from apparently healthy parent. In the fifth
case (Case 25, Table 2) the pregnancy was terminated
due to the type and severity of ultrasound anomalies.
Microarrays were introduced into the routine prenatal
setting approximately 3–4 years ago [3–5], and at first
used only in the case of fetuses with ultrasound anomal-
ies or abnormal karyotype results. The method was
proven to provide important additional diagnostic yield
and some diagnostic centres also evaluated the method
for testing the fetuses with increased nuchal translu-
cency. Some countries went even further and imple-
mented the aCGH for all invasive prenatal genetic
testing [9]. Two different approaches are being discussed
currently – one supports the implementation of the
aCGH for all prenatal testing, regardless of the indica-
tion for genetic testing [18, 19]. Grande et al. [8] have
shown that the clinically relevant CNV was present in
1,7% of pregnancies which underwent genetic testing
due to advanced maternal age or positive aneuploidy
screening (increased NT, abnormal result of maternal
serum screening), thus justifying the use of the method
in all invasive testing. The other perspective emphasizes
the importance of and challenges introduced by the
discovery of VOUS and so called risk factors – CNVs
with non-fully penetrant and mild phenotype, usually
inherited from a parent with minimal or no clinical fea-
tures. It is suggested that these CNVs exert a phenotypic
effect only in the presence of other genetic variants [20].
Both types of CNVs, the VOUS and risk factors, repre-
sent difficult counseling situations and place enormous
pressure on the expectant parents. But the pretest coun-
seling should include above mentioned findings, discuss
that with the parents before the test and therefore
minimize the chance of any undesirable situations.
Finally, genome-wide aCGH may uncover findings of
clinical significance, unrelated to the discovered ultra-
sound abnormalities, so called secondary findings. In
our series of the prenatal cases we identified 6 such
cases, all being a known non-fully penetrant microdele-
tion/microduplication syndrome.
Conclusions
To conclude, the aCGH incrementally improved the diag-
nostic yield in routine prenatal genetic testing and proved
to be an important first tier diagnostic test in the group of
fetuses with ultrasound anomalies and the additional test
in the fetuses with apparently balanced de novo chromo-
somal rearrangements. The pretest counseling sessions
are essential and the potential discovery of VOUS and
numerical aberrations with reduced penetrance should be
discussed in advance with the future parents.
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